|Publication Type||Journal Article|
|Year of Publication||2018|
|Authors||Iniguez, ABalboni, Stolte, B, Wang, EJue, Conway, ASaur, Alexe, G, Dharia, NV, Kwiatkowski, N, Zhang, T, Abraham, BJ, Mora, J, Kalev, P, Leggett, A, Chowdhury, D, Benes, CH, Young, RA, Gray, NS, Stegmaier, K|
|Date Published||2018 Jan 17|
Many cancer types are driven by oncogenic transcription factors that have been difficult to drug. Transcriptional inhibitors, however, may offer inroads into targeting these cancers. Through chemical genomics screening, we identified that Ewing sarcoma is a disease with preferential sensitivity to THZ1, a covalent small-molecule CDK7/12/13 inhibitor. The selective CDK12/13 inhibitor, THZ531, impairs DNA damage repair in an EWS/FLI-dependent manner, supporting a synthetic lethal relationship between response to THZ1/THZ531 and EWS/FLI expression. The combination of these molecules with PARP inhibitors showed striking synergy in cell viability and DNA damage assays in vitro and in multiple models of Ewing sarcoma, including a PDX, in vivo without hematopoietic toxicity.
|Alternate Journal||Cancer Cell|